Comparative Pharmacology
Head-to-head clinical analysis: CODEINE ASPIRIN APAP FORMULA NO 4 versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CODEINE ASPIRIN APAP FORMULA NO 4 versus WESTADONE.
CODEINE, ASPIRIN, APAP FORMULA NO. 4 vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug converted to morphine, which acts as a μ-opioid receptor agonist, producing analgesia, cough suppression, and euphoria. Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, leading to analgesia, anti-inflammatory, and antipyretic effects. Acetaminophen (APAP) inhibits cyclooxygenase (COX) enzymes, but its central action via cannabinoid receptors may contribute to analgesia and antipyresis.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Codeine: 2.5-3 hours (terminal half-life); Aspirin: 15-20 minutes (parent drug), 2-3 hours for salicylate at low doses, up to 15-30 hours at high doses (due to saturable metabolism); Acetaminophen: 2-3 hours (therapeutic doses), prolonged in overdose (>4 hours).
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Codeine: Renal (90% as metabolites, 10% unchanged). Aspirin: Renal (75% as salicyluric acid, 10% as salicyl glucuronides, 10% as gentisic acid, <10% unchanged). Acetaminophen: Renal (90-100% as glucuronide and sulfate conjugates, <5% unchanged).
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist